AU2020344829A1 — VS-6063 in combination with CH5126766 for the treatment of cancer
Assigned to Institute of Cancer Research Royal Cancer Hospital · Expires 2022-03-03 · 4y expired
What this patent protects
This invention relates to methods comprising administering a FAK inhibitor (e.g., VS-6063) in combination with a dual RAF/MEK inhibitor (e.g., CH5126766) that are useful in the treatment of abnormal cell growth, such as cancer, in a subject such as humans.
USPTO Abstract
This invention relates to methods comprising administering a FAK inhibitor (e.g., VS-6063) in combination with a dual RAF/MEK inhibitor (e.g., CH5126766) that are useful in the treatment of abnormal cell growth, such as cancer, in a subject such as humans.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.